Daily Medication Pearl: Evinacumab-dgnb (Evkeeza)
Evinacumab-dgnb (Evkeeza) is indicated as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia.
Medication Pearl of the Day: Evinacumab-dgnb (Evkeeza)
Indication: Evinacumab-dgnb (Evkeeza) is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
- Dosing: The recommended dose of evinacumab-dgnb is 15 mg/kg administered by intravenous infusion once monthly (every 4 weeks)
- Dosage forms: Injection 345 mg/2.3 mL (150 mg/mL) and 1200 mg/8 mL (150 mg/mL) solution in single-dose vials.
- Adverse events: Common adverse reactions (≥5%) were nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea
- Mechanism of action: Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase and endothelial lipase.